Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS, INC. | v464152_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS, INC. | v464152_ex31-1.htm |
| EX-10.1 - EXHIBIT 10.1 - INTERCEPT PHARMACEUTICALS, INC. | v464152_ex10-1.htm |
| 10-Q - FORM 10-Q - INTERCEPT PHARMACEUTICALS, INC. | v464152_10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Intercept Pharmaceuticals, Inc. (the “Company”) for the period ended March 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: May 10, 2017 | By: | /s/ Mark Pruzanski |
| Mark Pruzanski, M.D. | ||
| President and Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| Date: May 10, 2017 | By: | /s/ Sandip Kapadia |
| Sandip Kapadia | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) |